Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652416 | 0.83 | PTGS2 (0.76) | PTGS2KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL14176066 | 0.82 | MAP4K4 (0.48) | PTGS2KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL12670664 | 0.80 | TSHR (0.51) | KMT2AALDH1A1POLBMEN1MAPT | |
| SCHEMBL3080559 | 0.78 | PTGS2 (0.47) | PTGS2KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL26121053 | 0.76 | PTGS2 (0.56) | PTGS2KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL27207734 | 0.76 | ALDH1A1 (0.82) | KMT2AALDH1A1SMN1; SMN2POLBMEN1 | |
| SCHEMBL15051665 | 0.76 | PTGS2 (0.46) | PTGS2KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL27207753 | 0.75 | POLB (0.74) | PTGS2KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL12670668 | 0.75 | CA12 (0.59) | PTGS2KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL6681087 | 0.75 | ALDH1A1 (0.59) | KMT2AALDH1A1SMN1; SMN2POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-7947707-B2 | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-7947707-B2 | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20090306396-A1 | NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090306396-A1 | NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306396-A1 | NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | XDH, CBR3, CBR1 | PTGS2 1551/4885KMT2A 4106/4885ALDH1A1 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.